IvermectinSun 11:48 am Europe/London, 10 Jan 2021
In the round-up, yesterday we linked to video letter from Dr Tess Lawrie of the Evidence-Based Medicine Consultancy in Bath to the Prime Minister concerning the potential of Ivermectin to prevent and treat COVID-19. The video, as many readers found, swiftly and mysteriously disappeared from YouTube so we’ve moved the story up here to give it greater prominence. Dr Lawrie’s message is still available on the consultancy’s website, together with the report and the related press release (pdf) which provides more detail:
New British research has examined and pooled data from a wide range of international studies – including Argentina, Bangladesh, Iran, Pakistan, Spain, Egypt, India and the US – and found that the anti-parasitic medicine Ivermectin not only reduces deaths from COVID-19, but can be used to protect doctors and nurses – as well as others who have had “contacts‟ with ill people – from getting the infection.
The report was published last week by an independent UK-based medical research company, the Evidence-Based Medicine Consultancy Ltd (E-BMC).
The research was conducted to support the recent findings of Dr Pierre Kory and clinical experts of the Front Line COVID-19 Critical Care Alliance (FLCCC) in the US. Doctors around the world are now working together to raise awareness of this life-saving medicine which probably reduces the risk of a person dying from COVID-19 by between 65% and 95%.
In addition, the researchers believe that ivermectin should be offered as a prophylactic measure to health care workers as soon as possible because the analysis shows that ivermectin substantially reduces COVID-19 infections in these at risk groups.
The conclusions of the new global research are so clear that it is believed Ivermectin should be viewed as an essential drug to reduce the severity of illness and fatalities caused by the COVID-19 virus.
In most studies included in the review, the doses of Ivermectin given were similar to those given for common parasitic infections in humans (e.g. 0.2mg/kg orally, equivalent to a 12mg tablet for a 6kg adult).
Commenting on the research, Dr Tess Lawrie of the E-BMC, said, “This is really good news. Ivermectin will have a significant impact on the battle against COVID-19
Meanwhile, over in the USA, Drs Pierre Kory and Paul Marik of the Front Line COVID-19 Critical Care Alliance appeared before the National Institutes of Health COVID-19 Treatment Guidelines Panel to present the latest evidence on ivermectin. The press release (pdf) which followed said:
The doctors explained to the panel that numerous clinical studies, including peer-reviewed randomized controlled trials, showed large magnitude benefits of ivermectin in prophylaxis, early treatment and also in late-stage disease. Taken together, the doctors reported that the dozens of clinical trials that have now emerged from around the world are substantial enough to reliably assess clinical efficacy.
Specifically, the FLCCC physicians and Dr. Hill presented data from 18 randomized controlled trials that included over 2,100 patients. The trial results demonstrated that ivermectin produces faster viral clearance, faster time to hospital discharge, faster time to clinical recovery, and a 75% reduction
in mortality rates.
“In order to save thousands who will die while waiting for their turn to receive the vaccine, it is imperative that treatment guidelines issued by the NIH over four months ago be updated to reflect the strength of the data for ivermectin in prophylaxis, early treatment, and late-stage disease,” said Dr. Kory, FLCCC president, following the hearing.
Ivermectin has not yet been approved by any of the relevant authorities in the UK as a COVID-19 treatment, but with so much emphasis being placed on rollout of the various vaccines it is worth considering that there other potential drugs that could have be part of the solution.